See news from the Bioscience and Technology Business Center (BTBC), updates on our growth, news from our tenant companies and partners, and media coverage.
MassChallenge Boston Announces 2020 Cohort 100 early-stage, high-impact companies gain access to global network of experts and resources. Two dates set for the public to connect with new cohort online. JUNE 2, 2020 (BOSTON, MA) – MassChallenge, a global network of zero-equity startup accelerators, today announced the 100 early-stage startups that will join the 2020 MassChallenge […]
June 11, 2020 By Anne Christiansen-Bullers Jasmine Salem, lab technician at Sinochips Diagnostics, prepares pipette tips for for a machine called the Roche Cobas E411. It’s part of the testing process that ultimately delivers results about the coronavirus that leads to COVID-19. Sinochips Diagnostics, a private laboratory operating on the campus of the University of […]
June 01, 2020 SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The full text of that letter is as follows: To Our Valued Captisol Customers, Ligand is in a period of momentous planning and scale-up. As you may know, Captisol is a key ingredient […]
REMDESIVIR, THE DRUG THERAPY RECENTLY AUTHORIZED UNDER EMERGENCY-USE PROTOCOL FOR COVID-19, CONTAINS CRUCIAL INGREDIENT FROM THE UNIVERSITY OF KANSAS
Mon, 06/01/2020 LAWRENCE — When the Food and Drug Administration issued an emergency-use authorization for the investigational pharmaceutical remdesivir to treat COVID-19 on May 1, in part it was due to pioneering work performed by pharmaceutical chemists at the University of Kansas School of Pharmacy in 1990. Today, KU graduates still hold important jobs at […]
FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCKTM (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
May 15, 2020 QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in INVICTUS Phase 3 Study NDA Approved 3 Months Prior to Action Date Under FDA’s Real Time Oncology Review (RTOR) Deciphera to Host Conference Call Today at 5:00 PM Eastern Time WALTHAM, Mass.–(BUSINESS WIRE)–May 15, 2020– Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) […]